I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Kosemund, Dirk
11
results:
Search for persons
X
Format
Online (11)
Mediatypes
Articles (Online) (7)
OpenAccess-fulltext (4)
Languages
german (2)
english (7)
Sorted by: Relevance
Sorted by: Year
?
1
Changing for the Better: Discovery of the Highly Potent and..:
Lücking, Ulrich
;
Kosemund, Dirk
;
Böhnke, Niels
...
Journal of Medicinal Chemistry. 64 (2021) 15 - p. 11651-11674 , 2021
Link:
https://doi.org/10.1021/..
?
2
Treating Cancer by Spindle Assembly Checkpoint Abrogation: ..:
Schulze, Volker K.
;
Klar, Ulrich
;
Kosemund, Dirk
...
Journal of Medicinal Chemistry. 63 (2020) 15 - p. 8025-8042 , 2020
Link:
https://doi.org/10.1021/..
?
3
Identification of Atuveciclib (BAY 1143572), the First High..:
Lücking, Ulrich
;
Scholz, Arne
;
Lienau, Philip
...
ChemMedChem. 12 (2017) 21 - p. 1776-1793 , 2017
Link:
https://doi.org/10.1002/..
?
4
Impact of isotype-selective estrogen receptor agonists on o..:
Hegele-Hartung, Christa
;
Siebel, Philip
;
Peters, Olaf
...
Proceedings of the National Academy of Sciences. 101 (2004) 14 - p. 5129-5134 , 2004
Link:
https://doi.org/10.1073/..
?
5
Impact of Isotype-Selective Estrogen Receptor Agonists on O..:
Hegele-Hartung, Christa
;
Siebel, Philip
;
Peters, Olaf
...
Proceedings of the National Academy of Sciences of the United States of America. 101 (2004) 14 - p. 5129-5134 , 2004
Link:
https://www.jstor.org/st..
?
6
Synthesen des ?16-17-Iodids und -Triflats von Androsta-4-en..:
Schweder, Bernd
;
Uhlig, Egon
;
Kosemund, Dirk
Journal f�r Praktische Chemie/Chemiker-Zeitung. 335 (1993) 2 - p. 201-204 , 1993
Link:
https://doi.org/10.1002/..
?
7
?16-20-Ketosteroide durch C2-Verl�ngerung aus ?16-17-substi..:
Schweder, Bernd
;
Uhlig, Egon
;
D�ring, Manfred
.
Journal f�r Praktische Chemie/Chemiker-Zeitung. 335 (1993) 5 - p. 439-444 , 1993
Link:
https://doi.org/10.1002/..
?
8
Identification of Atuveciclib (BAY 1143572), the First High..:
Lücking, Ulrich
;
Scholz, Arne
;
Lienau, Philip
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698704/. , 2017
Link:
http://www.ncbi.nlm.nih...
?
9
Impact of isotype-selective estrogen receptor agonists on o..:
Hegele-Hartung, Christa
;
Siebel, Philip
;
Peters, Olaf
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC387385. , 2004
Link:
http://www.ncbi.nlm.nih...
?
10
Changing for the Better: Discovery of the Highly Potent and..:
Ulrich Lücking (2614105)
;
Dirk Kosemund (8769683)
;
Niels Böhnke (11139232)
...
https://figshare.com/articles/dataset/Changing_for_the_Better_Discovery_of_the_Highly_Potent_and_Selective_CDK9_Inhibitor_VIP152_Suitable_for_Once_Weekly_Intravenous_Dosing_for_the_Treatment_of_Cancer/14988013. , 2021
Link:
https://doi.org/10.1021/..
?
11
Changing for the Better: Discovery of the Highly Potent and..:
Ulrich Lücking (2614105)
;
Dirk Kosemund (8769683)
;
Niels Böhnke (11139232)
...
https://figshare.com/articles/journal_contribution/Changing_for_the_Better_Discovery_of_the_Highly_Potent_and_Selective_CDK9_Inhibitor_VIP152_Suitable_for_Once_Weekly_Intravenous_Dosing_for_the_Treatment_of_Cancer/14988016. , 2021
Link:
https://doi.org/10.1021/..
1-11
